(Q40626624)

22 September 2017

title

Superior antitumour activity of S-1 in tumours with a high dihydropyrimidine dehydrogenase activity (English)

1 reference

22 September 2017

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(03)00513-6

21 March 2024

author name string

H. Fujiwara

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14556932

21 March 2024

M. Terashima

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14556932

21 March 2024

T. Irinoda

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14556932

21 March 2024

A. Takagane

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14556932

21 March 2024

K. Abe

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14556932

21 March 2024

T. Nakaya

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14556932

21 March 2024

H. Yonezawa

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14556932

21 March 2024

K. Oyama

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14556932

21 March 2024

M. Takahashi

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14556932

21 March 2024

K. Saito

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14556932

21 March 2024

T. Takechi

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14556932

21 March 2024

M. Fukushima

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14556932

21 March 2024

T. Shirasaka

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14556932

21 March 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14556932

21 March 2024

publication date

1 November 2003

1 reference

full work available at URL

22 September 2017

https://api.elsevier.com/content/article/PII:S0959804903005136?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(03)00513-6

https://api.elsevier.com/content/article/PII:S0959804903005136?httpAccept=text/plain

21 March 2024

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(03)00513-6

European Journal of Cancer

21 March 2024

published in

1 reference

22 September 2017

volume

39

1 reference

22 September 2017

issue

16

1 reference

22 September 2017

page(s)

2387-2394

1 reference

FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer

22 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900513-6

7 January 2021

Chemotherapy of gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900513-6

7 January 2021

Metabolism and mechanism of action of 5-fluorouracil

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900513-6

7 January 2021

Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900513-6

7 January 2021

Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900513-6

7 January 2021

Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900513-6

7 January 2021

Clinical application of biochemical modulation in cancer chemotherapy: biochemical modulation for 5-FU

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900513-6

7 January 2021

Phase II study of UFT plus leucovorin in colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900513-6

7 January 2021

Uracil-ftorafur: an oral fluoropyrimidine active in colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900513-6

7 January 2021

Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900513-6

7 January 2021

Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900513-6

7 January 2021

Prediction of sensitivity to fluoropyrimidines by metabolic and target enzyme activities in gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900513-6

7 January 2021

Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900513-6

7 January 2021

Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900513-6

7 January 2021

Pharmacokinetic analysis of free radicals by in vivo BCM (Blood Circulation Monitoring)-ESR method.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900513-6

7 January 2021

Modulation of anti-metabolite effects. Effects of thymidine on the efficacy of the quinazoline-based thymidylate synthetase inhibitor, CB3717

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900513-6

7 January 2021

Thymidylate synthase (TS) and ribonucleotide reductase (RNR) may be involved in acquired resistance to 5-fluorouracil (5-FU) in human cancer xenografts in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900513-6

7 January 2021

Effect of 5-fluorouracil on the synthesis and translation of polyadenylic acid-containing RNA from regenerating rat liver

3

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(03)00513-6

Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile

21 March 2024

5

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(03)00513-6

Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts

21 March 2024

15

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(03)00513-6

21 March 2024

Identifiers

1 reference

22 September 2017

1 reference